Download PDF
Klin Monbl Augenheilkd 2003; 220(11): 731-737
DOI: 10.1055/s-2003-44610
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Gentherapie bei Hornhauterkrankungen

Gene Therapy in Corneal DiseasesFriedrich  Hoffmann1 , Claas  Junghans2
  • 1Augenklinik, Universitätsklinikum Benjamin Franklin (UKBF), Freie Universität Berlin
  • 2Mologen, Berlin
Further Information

Publication History

Eingegangen: 14. Juli 2003

Angenommen: 21. August 2003

Publication Date:
21 November 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

In der Vergangenheit wurden euphorische Erwartungen in die Gentherapie geweckt, die aber bisher nicht nur nicht erfüllt, sondern im Gegenteil wegen eines Ausbleibens konkreter klinischer Erfolge sowie des Eintretens tragischer Zwischenfälle enttäuscht wurden. Trotz des großen Zukunftspotenzials der Gentherapie werden wohl für längere Zeit zahlreiche gentherapeutische Pilotstudien abgebrochen werden. Aber trotz aller Misserfolge werden Krankheiten für experimentelle Protokolle, die beispielsweise nur eine vorübergehenden Genexpression vorsehen oder solche, die sich auf einzelne Organe beschränken und daher nur eine niedrige Dosis des Vehikels (Vektors) benötigen, weiterhin Ziel experimenteller Gentransferversuche bleiben. Wegen seiner guten und selektiven Erreichbarkeit, des geringen Volumens und des dadurch bedingten geringen Bedarfs an Genfähren sowie seines besonderen immunologischen Status ist gerade das Auge als potenzielles Zielorgan hervorragend geeignet. Die Hornhauttransplantation ist eine Indikation mit verbesserbarer Prognose, die vom Methodenkatalog der Gentransferprotokolle profitieren kann. Die Hornhaut steht zudem vor einer Transplantation einem Gentransfer ex vivo zur Verfügung. Die Augenheilkunde könnte daher beim klinischen Gentransfer eine Pionierstellung einnehmen. Eine Literatursynopse beschreibt den gegenwärtigen Stand der experimentellen Verbesserung der Hornhauttransplantation, der Beeinflussung der Narbenbildung, der Neovaskularisation und der Herpesinfektion der Kornea. Das wesentliche Problem der Gentherapie ist die nicht zufrieden stellende Technik des Gentransfers. Die Schwierigkeiten und die aktuellen Verbesserungen werden erörtert.

Abstract

Gene therapy raised euphoric expectations in the past that have yet to be met and have even been lowered due to the absence of concrete clinical successes and the occurrence of some tragic incidents. In spite of the great future potential of gene therapy, numerous pilot studies in this field will probably be discontinued for a long time. However, despite these failures, diseases will continue to be the aim of gene transfer studies with experimental protocols using only temporary gene expression or those restricted to individual organs and thus requiring only a low dose of the vehicle (vector). The eye is exceptionally well suited as a potential target organ because of its good and selective accessibility, low volume and the resultant low number of gene ferries required as well as its special immunological status. The prognosis of corneal grafting can be improved and profit from the methods catalogue of gene transfer protocols. Moreover, the cornea can be used for ex vivo gene transfer before grafting. Ophthalmology could thus occupy a pioneer position in clinical gene transfer. A survey of the literature describes the current state of experimental improvement in corneal grafting, the effect on scarring, neovascularization, and herpetic corneal infection. The essential problem of gene therapy is the unsatisfactory gene transfer technique. Difficulties and current improvements are discussed.

Schlüsselwörter

Gentransfer - Vektoren - Hornhauttransplantation - Narbenbildung - Neovaskularisation - Herpesinfektion

Key words

Gene transfer - vectors - corneal grafting - scarring - neovascularization - herpes infection

Literatur

  • 1 Arancibia-Carcamo C V, Oral H B, Haskard D O, Larkin D F, George A J. Lipoadenofection-mediated gene delivery to the corneal endothelium: prospects for modulating graft rejection.  Transplantation. 1998;  65 62-67
    PubMedGoogle Scholar
  • 2 Bainbridge J W, Stephens C, Parsley K, Demaison C, Halfyard A, Thrasher A J, Ali R R. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium.  Gene Ther. 2001;  8 1665-1668
    CrossrefPubMedGoogle Scholar
  • 3 Behrens A, Gordon E M, Li L, Liu P X, Chen Z, Peng H, Bree L la, Anderson W F, Hall F L, McDonnell P J. Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze.  Invest Ophthalmol Vis Sci. 2002;  43 968-977
    PubMedGoogle Scholar
  • 4 Bradshaw J J, Obritsch W F, Cho B J, Gregerson D S, Holland E J. Ex vivo transduction of corneal epithelial progenitor cells using a retroviral vector.  Invest Ophthalmol Vis Sci. 1999;  40 230-235
    PubMedGoogle Scholar
  • 5 Chaum E, Hatton M P. Gene therapy for genetic and acquired retinal diseases.  Surv Ophthalmol. 2002;  47 449-469
    PubMedGoogle Scholar
  • 6 Comer R M, King W J, Ardjomand N, Theoharis S, George A J, Larkin D F. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.  Invest Ophthalmol Vis Sci. 2002;  43 1095-1103
    PubMedGoogle Scholar
  • 7 Cordeiro M F, Mead A, Ali R R, Alexander R A, Murray S, Chen C, York-Defalco C, Dean N M, Schultz G S, Khaw P T. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome.  Gene Ther. 2003;  10 59-71
    CrossrefPubMedGoogle Scholar
  • 8 Cui B, Carr D J. A plasmid construct encoding murine interferon beta antagonizes the replication of herpes simplex virus type I in vitro and in vivo.  J Neuroimmunol. 2000;  108 92-102
    CrossrefPubMedGoogle Scholar
  • 9 Garcia-Sanchez F, Pizzorno G, Fu S Q, Nanakorn T, Krause D S, Liang J, Adams E, Leffert J J, Yin L H, Cooperberg M R, Hanania E, Wang W L, Won J H, Peng X Y, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth A B. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.  Blood. 1998;  92 672-682
    PubMedGoogle Scholar
  • 10 Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency.  Int J Hematol. 2002;  76 295-298
    PubMedGoogle Scholar
  • 11 Hacein-Bey-Abina S, Kalle C von, Schmidt M, LeDeist F, Wulffraat N, McIntyre E, Radford I, Villeval J L, Fraser C C, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.  N Engl J Med. 2003;  348 255-256
    CrossrefPubMedGoogle Scholar
  • 12 Hart S L, Arancibia-Carcamo C V, Wolfert M A, Mailhos C, O'Reilly N J, Ali R R, Coutelle C, George A J, Harbottle R P, Knight A M, Larkin D F, Levinsky R J, Seymour L W, Thrasher A J, Kinnon C. Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector.  Hum Gene Ther. 1998;  9 575-585
    PubMedGoogle Scholar
  • 13 Hoffmann F, Zhang E P, Mueller A, Schulte F, Foss H D, Franke J, Coupland S E. Contribution of lymphatic drainage system in corneal allograft rejection in mice.  Graefes Arch Clin Exp Ophthalmol. 2001;  239 850-858
    PubMedGoogle Scholar
  • 14 Igarashi T, Miyake K, Suzuki N, Kato K, Takahashi H, Ohara K, Shimada T. New strategy for in vivo transgene expression in corneal epithelial progenitor cells.  Curr Eye Res. 2002;  24 46-50
    CrossrefPubMedGoogle Scholar
  • 15 Inoue T, Inoue Y, Hayashi K, Yoshida A, Nishida K, Shimomura Y, Fujisawa Y, Aono A, Tano Y. Topical administration of HSV gD-IL-2 DNA is highly protective against murine herpetic stromal keratitis.  Cornea. 2002;  21 106-110
    CrossrefPubMedGoogle Scholar
  • 16 Kagaya F, Hori J, Kamiya K, Kaji Y, Oshika T, Amano S, Yamagami S, Tsuru T, Tanaka S, Matsuda H, Yagita H, Okumura K. Inhibition of murine corneal allograft rejection by treatment with antibodies to CD80 and CD86.  Exp Eye Res. 2002;  74 131-139
    CrossrefPubMedGoogle Scholar
  • 17 Kamata Y, Okuyama T, Kosuga M, O'Hira A, Kanaji A, Sasaki K, Yamada M, Azuma N. Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII.  Mol Ther. 2001;  4 307-312
    CrossrefPubMedGoogle Scholar
  • 18 Klebe S, Sykes P J, Coster D J, Bloom D C, Williams K A. Gene transfer to ovine corneal endothelium.  Clin Experiment Ophthalmol. 2001;  29 316-322
    CrossrefPubMedGoogle Scholar
  • 19 Klebe S, Sykes P J, Coster D J, Krishnan R, Williams K A. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10.  Transplantation. 2001;  71 1214-1220
    PubMedGoogle Scholar
  • 20 König Merediz S A, Zhang E P, Wittig B, Hoffmann F. Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation.  Graefes Arch Clin Exp Ophthalmol. 2000;  238 701-707
    CrossrefPubMedGoogle Scholar
  • 21 Krauzewicz N, Cox C, Soeda E, Clark B, Rayner S, Griffin B E. Sustained ex vivo and in vivo transfer of a reporter gene using polyoma virus pseudocapsids.  Gene Ther. 2000;  7 1094-1102
    CrossrefPubMedGoogle Scholar
  • 22 Kubo H, Gardner T A, Wada Y, Koeneman K S, Gotoh A, Yang L, Kao C, Lim S D, Amin M B, Yang H, Black M E, Matsubara S, Nakagawa M, Gillenwater J Y, Zhau H E, Chung L W. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.  Hum Gene Ther. 2003;  14 227-241
    CrossrefPubMedGoogle Scholar
  • 23 Kuffova L, Lumsden L, Vesela V, Taylor J A, Filipec M, Holan V, Dick A D, Forrester J V. Kinetics of leukocyte and myeloid cell traffic in the murine corneal allograft response.  Transplantation. 2001;  72 1292-1298
    PubMedGoogle Scholar
  • 24 Lai C M, Spilsbury K, Brankov M, Zaknich T, Rakoczy P E. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA.  Exp Eye Res. 2002;  75 625-634
    CrossrefPubMedGoogle Scholar
  • 25 Lai Y K, Shen W Y, Brankov M, Lai C M, Constable I J, Rakoczy P E. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy.  Gene Ther. 2002;  9 804-813
    CrossrefPubMedGoogle Scholar
  • 26 Larkin D F, Oral H B, Ring C J, Lemoine N R, George A J. Adenovirus-mediated gene delivery to the corneal endothelium.  Transplantation. 1996;  61 363-370
    PubMedGoogle Scholar
  • 27 Liu H, Wu X, Xiao H, Kappes J C. Targeting human immunodeficiency virus (HIV) type 2 integrase protein into HIV type 1.  J Virol. 1999;  73 8831-8836
    PubMedGoogle Scholar
  • 28 Lopez J V, Culver M, Stephens J C, Johnson W E, O'Brien S J. Rates of nuclear and cytoplasmic mitochondrial DNA sequence divergence in mammals.  Mol Biol Evol. 1997;  14 277-286
    PubMedGoogle Scholar
  • 29 Lui V W, Falo L D, Huang L. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo.  J Gene Med. 2001;  3 384-393
    CrossrefPubMedGoogle Scholar
  • 30 Masuda I, Matsuo T, Yasuda T, Matsuo N. Gene transfer with liposomes to the intraocular tissues by different routes of administration.  Invest Ophthalmol Vis Sci. 1996;  37 1914-1920
    PubMedGoogle Scholar
  • 31 Mohan R R, Schultz G S, Hong J W, Wilson S E. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access.  Exp Eye Res. 2003;  76 373-383
    CrossrefPubMedGoogle Scholar
  • 32 Moore J E, McMullen T C, Campbell I L, Rohan R, Kaji Y, Afshari N A, Usui T, Archer D B, Adamis A P. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy.  Invest Ophthalmol Vis Sci. 2002;  43 2905-2915
    PubMedGoogle Scholar
  • 33 Müller A, Zhang E P, Schroff M, Wittig B, Hoffmann F. Influence of ballistic gene transfer on antigen-presenting cells in murine corneas.  Graefes Arch Clin Exp Ophthalmol. 2002;  240 851-859
    PubMedGoogle Scholar
  • 34 Nam N H, Parang K. Current targets for anticancer drug discovery.  Curr Drug Targets. 2003;  4 159-179
    CrossrefPubMedGoogle Scholar
  • 35 Noisakran S, Campbell I L, Carr D J. Ectopic expression of DNA encoding IFN-α 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis.  J Immunol. 1999;  162 4184-4190
    PubMedGoogle Scholar
  • 36 Noisakran S, Carr D J. Topical application of the cornea post-infection with plasmid DNA encoding interferon-α1 but not recombinant interferon-αA reduces herpes simplex virus type 1-induced mortality in mice.  J Neuroimmunol. 2001;  121 49-58
    CrossrefPubMedGoogle Scholar
  • 37 Noisakran S J, Carr D J. Therapeutic efficacy of DNA encoding IFN-α1 against corneal HSV-1 infection.  Curr Eye Res. 2000;  20 405-412
    CrossrefPubMedGoogle Scholar
  • 38 Oral H B, Larkin D F, Fehervari Z, Byrnes A P, Rankin A M, Haskard D O, Wood M J, Dallman M J, George A J. Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea.  Gene Ther. 1997;  4 639-647
    CrossrefPubMedGoogle Scholar
  • 39 Oshima Y, Sakamoto T, Hisatomi T, Tsutsumi C, Sassa Y, Ishibashi T, Inomata H. Targeted gene transfer to corneal stroma in vivo by electric pulses.  Exp Eye Res. 2002;  74 191-198
    CrossrefPubMedGoogle Scholar
  • 40 Oshima Y, Sakamoto T, Yamanaka I, Nishi T, Ishibashi T, Inomata H. Targeted gene transfer to corneal endothelium in vivo by electric pulse.  Gene Ther. 1998;  5 1347-1354
    CrossrefPubMedGoogle Scholar
  • 41 Plank C, Oberhauser B, Mechtler K, Koch C, Wagner E. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems.  J Biol Chem. 1994;  269 12918-12924
    PubMedGoogle Scholar
  • 42 Pleyer U, Bertelmann E, Rieck P, Hartmann C, Volk H D, Ritter T. Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4.  Graefes Arch Clin Exp Ophthalmol. 2000;  238 531-536
    CrossrefPubMedGoogle Scholar
  • 43 Pleyer U, Groth D, Hinz B, Keil O, Bertelmann E, Rieck P, Reszka R. Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells.  Exp Eye Res. 2001;  73 1-7
    CrossrefPubMedGoogle Scholar
  • 44 Plskova J, Duncan L, Holan V, Filipec M, Kraal G, Forrester J V. The immune response to corneal allograft requires a site-specific draining lymph node.  Transplantation. 2002;  73 210-215
    PubMedGoogle Scholar
  • 45 Rayner S A, Larkin D F, George A J. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival.  Invest Ophthalmol Vis Sci. 2001;  42 1568-1573
    PubMedGoogle Scholar
  • 46 Rubanyi G M. The future of human gene therapy.  Mol Aspects Med. 2001;  22 113-142
    PubMedGoogle Scholar
  • 47 Sakamoto T, Oshima Y, Nakagawa K, Ishibashi T, Inomata H, Sueishi K. Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits intracameral fibrin formation and corneal cloudiness.  Hum Gene Ther. 1999;  10 2551-2557
    CrossrefPubMedGoogle Scholar
  • 48 Satoh T, Timme T L, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N, Mouraviev V, Thompson T C. Adenoviral Vector-Mediated mRTVP-1 Gene Therapy for Prostate Cancer.  Hum Gene Ther. 2003;  14 91-101
    CrossrefPubMedGoogle Scholar
  • 49 Schakowski F, Gorschluter M, Junghans C, Schroff M, Buttgereit P, Ziske C, Schottker B, König Merediz S A, Sauerbruch T, Wittig B, Schmidt-Wolf I G. A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA.  Mol Ther. 2001;  3 793-800
    CrossrefPubMedGoogle Scholar
  • 50 Shewring L, Collins L, Lightman S L, Hart S, Gustafsson K, Fabre J W. A nonviral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins.  Transplantation. 1997;  64 763-769
    CrossrefPubMedGoogle Scholar
  • 51 Stechschulte S U, Joussen A M, Recum H A von, Poulaki V, Moromizato Y, Yuan J, D'Amato R J, Kuo C, Adamis A P. Rapid ocular angiogenic control via naked DNA delivery to cornea.  Invest Ophthalmol Vis Sci. 2001;  42 1975-1979
    PubMedGoogle Scholar
  • 52 Tan P H, King W J, Chen D, Awad H M, Mackett M, Lechler R I, Larkin D F, George A J. Transferrin receptor-mediated gene transfer to the corneal endothelium.  Transplantation. 2001;  71 552-560
    PubMedGoogle Scholar
  • 53 Tanelian D L, Barry M A, Johnston S A, Le T, Smith G. Controlled gene gun delivery and expression of DNA within the cornea.  Biotechniques. 1997;  23 484-488
    PubMedGoogle Scholar
  • 54 Tsai M L, Chen S L, Chou P I, Wen L Y, Tsai R J, Tsao Y P. Inducible adeno-associated virus vector-delivered transgene expression in corneal endothelium.  Invest Ophthalmol Vis Sci. 2002;  43 751-757
    PubMedGoogle Scholar
  • 55 Tsubota K, Inoue H, Ando K, Ono M, Yoshino K, Saito I. Adenovirus-mediated gene transfer to the ocular surface epithelium.  Exp Eye Res. 1998;  67 531-538
    CrossrefPubMedGoogle Scholar
  • 56 Wang X, Appukuttan B, Ott S, Patel R, Irvine J, Song J, Park J H, Smith R, Stout J T. Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector.  Gene Ther. 2000;  7 196-200
    CrossrefPubMedGoogle Scholar
  • 57 Wu G Y, Wu C H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system.  J Biol Chem. 1987;  262 4429-4432
    PubMedGoogle Scholar
  • 58 Yamagami S, Dana M R, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation.  Cornea. 2002;  21 405-409
    CrossrefPubMedGoogle Scholar
  • 59 Zhang E P, Muller A, Schulte F, Konig M S, Sack F, Junghans C, Wittig B, Hoffmann F. Minimizing side effects of ballistic gene transfer into the murine corneal epithelium.  Graefes Arch Clin Exp Ophthalmol. 2002;  240 114-119
    PubMedGoogle Scholar

Prof. Dr. Friedrich Hoffmann

Freie Universität Berlin · Universitätsklinikum Benjamin Franklin · Augenklinik und Poliklinik

Hindenburgdamm 30

12200 Berlin

Email: fhoffman@zedat.fu-berlin.de

      >